Panelists discuss how nonstatin agents are chosen and when combination therapy should be introduced for high-risk patients.
In an interview with The American Journal of Managed Care® ( AJMC®), Mike Camacho, president of SLTCM, identifies 5 key strategies that ACOs can utilize to improve care and achieve meaningful savings, ...
Treadmill stress echocardiography (TSE) reveals hidden physiologic limitations in patients with asymptomatic hypertrophic cardiomyopathy (HCM), aiding in diagnosis and prognosis. Many patients with ...
Sibeprenlimab gains accelerated approval from the FDA for IgA nephropathy, showing significant proteinuria reduction and ...
Panelists discuss how overcoming logistical and perceptual barriers will drive wider adoption of SC therapies in NSCLC.
Key End Points for Providers to Consider With New Multiple Myeloma Therapies: Hearn Jay Cho, MD, PhD
Hearn Jay Cho, MD, PhD, chief medical officer at the Multiple Myeloma Research Foundation, shared insights on what end points ...
“The monoclonal antibodies rituximab, ocrelizumab, ofatumumab (Kesimpta), and ublituximab (Briumvi) provide outstanding ...
While limited data suggest loncastuximab tesirine plus rituximab may be active in the third line, larger cohorts and ...
Eleanor Perfetto, PhD, explores how most favored nation policy relates to broader drug pricing and cost-effectiveness debates ...
Zachary Contreras from Sharp Health Plan discusses findings from the AMCP Nexus study showing that dextromethorphan-bupropion ...
Zachary Contreras from Sharp Health Plan explains how managed care organizations can support early adoption of DM-BUP to ...
Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback